Tvardi Therapeutics, Inc. (TVRD)
NASDAQ: TVRD · Real-Time Price · USD
1.150
-0.090 (-7.26%)
At close: Oct 2, 2026, 4:00 PM EDT
1.170
+0.020 (1.74%)
After-hours: Oct 2, 2026, 7:30 PM EDT

Tvardi Therapeutics Stock Forecast

TVRD's stock price has decreased by -96.96% in the past year and price targets may not have had time to catch up.

Stock Price Forecast

According to 9 analysts polled by S&P Global, Tvardi Therapeutics stock has a consensus rating of "Buy" and an average price target of $9.25. The average 1-year stock price forecast is 704.35% higher than the current stock price, while the lowest is $3.00 (+160.87%) and the highest is $14 (+1,117.39%).

Price Target: $9.25 (+704.35%)
Analyst Consensus: Buy

Price Target

Chart
TargetLowAverageMedianHigh
Price$3.00$9.25$10$14
Change+160.87%+704.35%+769.57%+1117.4%

Analyst Ratings

The average analyst rating for Tvardi Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Chart
RatingApr '26May '26Jun '26Jul '26Aug '26Sep '26
Strong Buy445545
Buy000222
Hold333111
Sell111111
Strong Sell000000
Total889989

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
JonesTrading
JonesTrading
Buy
Reiterates
$12 → $10
BuyReiterates$12 → $10+769.57%Sep 15, 2026
Lucid Capital
Lucid Capital
Buy
Initiates
$6 → $14
BuyInitiates$6 → $14+1,117.39%Sep 8, 2026
H.C. Wainwright
H.C. Wainwright
Buy
Maintains
$9
BuyMaintains$9+682.61%Aug 21, 2026
Unknown Analyst
Cantor Fitzgerald
No rating
Cantor Fitzgerald
Hold
Maintains
n/a
HoldMaintainsn/an/aAug 20, 2026
BTIG
BTIG
Buy
Maintains
$5
BuyMaintains$5+334.78%Aug 20, 2026
More Analyst Ratings

Financial Forecast

Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-2.30
from -2.46
EPS Next Year
-2.24
from -2.30
Fiscal YearFY 2022FY 2023FY 2024FY 2025FY 2026
Period EndingDec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025Dec 31, 2026
Revenue
-----
Operating Income
-21.19M-18.67M-28.11M-26.75M-26.22M
Net Income
-20.54M-17.35M-29.40M-18.21M-25.97M
EPS
----2.46-2.30
Free Cash Flow
-----26.88M
No. Analysts
----8
EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue202620272028
Highn/a
Avgn/a
Lown/a

Revenue Growth

Revenue Growth20272028
High-
Avg-
Low-

EPS Forecast

EPS202620272028
High-1.60
Avg-2.30
Low-3.02

EPS Growth

EPS Growth202620272028
High-
Avg-
Low-